Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis.

It is stored and released from adipose tissue, so its effects can continue long after dosage stops.

Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days,[2] which make dosing difficult.

While acitretin is less lipophilic and has a half-life of only 50 hours, it is partly metabolized to etretinate in the body,[2] so that it is still a long-acting teratogen and pregnancy is prohibited for two years after therapy.

[3] Side effects are those typical of hypervitaminosis A, most commonly[4] The drug was approved by FDA in 1986 to treat severe psoriasis.